Serina Therapeutics

Executive Summary

Serina Therapeutics is a clinical-stage biotechnology company developing a next-generation polymer conjugation platform, POZ™, to improve the pharmacokinetics of established small molecule drugs. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease by enabling a simple, twice-weekly subcutaneous injection, potentially replacing complex continuous infusion therapies. The company utilizes the 505(b)(2) regulatory pathway, which leverages existing safety data to accelerate development and reduce risk. SER-252 is currently in a Phase 1 clinical trial (NCT07422675) that began recruiting in February 2026, with estimated completion in January 2027. Additionally, Serina has a prior candidate, SER-214, though its status is uncertain. The company's strategy aims to address significant unmet need in Parkinson's disease, where current apomorphine formulations require cumbersome administration. With a public listing (no ticker provided) and an estimated valuation of ~$26 million, Serina represents an early-stage opportunity in drug delivery innovation.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim data readout for SER-25270% success
• 2026Potential partnership or licensing deal for POZ platform40% success
• 2027Initiation of Phase 2 trial for SER-25250% success